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Correlation between In Vivo and In Vitro Efficacy of Antimicrobial Agents
against Foreign Body Infections
A. F. Widmer, R. Frei, Z. Rajacic, and W. Zimmerli From the Departments of Internal Medicine and Research and the
Bacteriology Laboratory, University Hospital, Basel, Switzerland
Implant-associated infections are often resistant to antibiotic therapy. Routine sensitivity tests
fail to predict therapeutic success. Therefore experimental in vitro tests were sought that would
better correlate with drug efficacy in device-related infections. The activity of six different antibi-
otics against methicillin-resistant Staphylococcus epidermidis was investigated. In vivo studies
were performed with the guinea pig tissue-cage animal model; in vitro studies with minimum
inhibiting and bactericidal concentrations, time-kill studies of growing and stationary-phase
microorganisms, the killing of glass-adherent S. epidermidis. Drug efficacy on stationary and
adherent microorganisms, but not minimum inhibiting concentrations, predicted the outcome
of device-related infections. Rifampin cured 12 of 12 infections and was also the most efficient
drug in any experimental in vitro test. Similarly, the failure of ciproftoxacin to eradicate foreign
body infections correlated with its low efficacy on stationary-phase and adherent S. epidermidis.
Device-related infections often persist until the device is
removed, even if the given antibiotic has a low minimum in-
hibiting concentration (MIC) for the causing microorganism
[1]. The preferential bacterial colonization ofbiomaterials plus
a local immunodeficiency explain the high infective suscepti-
bility of implants and the persistence of such infections [2-4].
Bacteria develop a survival mode by adhering to inert sur-
faces and producing a biofilm [5-7]. Possibly the mode of
growth and the adherence of bacteria to bioimplants explain
the failure of certain antibiotics to cure device-related infec-
tions.
To date, no standardized antimicrobial susceptibility test
is availableto evaluatedrug activity on adherent bacteria. MIC
and minimum bactericidal concentration (MBC) evaluate the
drug efficacy on planktonic bacteria in logarithmic phases of
growth [8, 9], a situation far from that of adherent bacteria
[5]. The activity of many antimicrobial agents strictly depends
on the phase of bacterial growth [10]. MICs and MBCs are
much higher for most drugs if tests are performed with partly
adherent bacteria [11].
In the present study, we tested the efficacy of different anti-
microbial agents in the treatment of guinea pig implant
infections caused by a weak slime-producing strain of
Staphylococcus epidermidis. To evaluate the in vitro efficacy
Received 30 May 1989; revised 6 November 1989.
Presented in part at the 28th Interscience Conference on Antimicrobial
Agents and Chemotherapy, Los Angeles, October 1988.
Financial support: Lilly Research Laboratories, Indianapolis, and Hyland
Therapeutic Divisions, Travenol Laboratories, Glendale, CA (to A. F. W.).
W. Z. received a career development award from the Swiss National Science
Foundation.
Reprints and correspondence: Dr. W. Zimmerli, Departments of Medi-
cine and Research, University Hospital, CH-4031 Basel, Switzerland.
The Journal of Infectious Diseases 1990;162:96-102
© 1990 by The University of Chicago. All rights reserved.
0022-1899/90/6201-0015$01.00
of antibiotics, we modified the MBC test procedure and de-
veloped a novel assay for testing adherent bacteria. We ana-
lyzed parameters that could predict the clinical outcome of
device-related infections by comparing pharmacokinetic
parameters, routine-susceptibility tests, and drug efficacy on
nongrowing and adherent staphylococci in an experimental
model of foreign body infections [2, 3, 12].
Materials and Methods
Bacteria and antibiotics. The test strain for most experiments
was a methicillin-resistant S. epidermidis. This strain (B3972) was
a clinicalisolate from a blood culture of a patientwith catheter-related
septicemia. Identification was determined by a Staphident strip (API,
La Balme les Grottes, France). It had a distinct susceptibility pat-
tern including resistance to methicillin, cotrimoxazole, erythromy-
cin, gentamicin, and tobramycin and sensitivity of ciprofloxacin,
vancomycin, daptomycin, teicoplanin, and netilmicin. Such an an-
timicrobial susceptibility pattern is known to be as discriminating
as plasmid profile analysis [13]. The S. epidermidis B3972 revealed
weak slime production [14, 15].
For control experiments, a rifampin-resistant variant of S. epider-
midis B3972 (MIC >4 jLg/ml) was selected by serial exposure of
bacteria to increasing subinhibitory concentrations of rifampin. With
this strain we tested whether a possible synergistic effectof rifampin
combinations would depend on the bacterial killing of rifampin or
on a nonspecific property (e.g., antiadherent effect) of this drug. In
some experiments another strain, a moderate-to-strong slime-pro-
ducing, methicillin-resistant S. epidermidis (ATCC35983) wasused
[15]. Working cultures were maintained on blood agar and trans-
ferred weekly.A new aliquot of the initial strain, stored in skim milk
at -70°C, was cultured every 3 months.
Slime production was qualitatively determined [14]. Control ex-
periments to exclude bacterial clumping were performed by direct
microscopy and serial sonication of samples ~9 min with 60 W/min
(Labsonic 2000; B. Braun Instruments, Burlingame, CA). Bacterial
clumping was not observed with either method. The following an-
timicrobial agents, provided by the manufacturers, were evaluated:
JID 1990;162 (July) Treatment of Foreign Body Infections 97
ciprofloxacin (Bayer AG, Wuppertal, FRG), rifampin (Ciba-Geigy,
Basel, Switzerland), netilmicin (Schering, Kenilworth, NJ), van-
comycin and daptomycin (Eli Lilly, Indianapolis), and teicoplanin
(LePetit, Milan, Italy).
Animal model. We used a previously described foreign-body an-
imal model [2, 3, 12]. In brief, four sterile polytetrafluorethylene
(Teflon) tubes (32 x 10 mm), perforated by 130 regularly spaced
holes (tissue cages; Ciba-Geigy) were aseptically implanted into the
flanks of albino guinea pigs weighing 600-1100 g. Experiments were
started after complete healing of wounds, "-'2-4 weeks after sur-
gery. Before each experiment, interstitial fluid accumulating in the
tissue cages was checked for sterility.
At day 0, for each experiment, 16 tissue cages were infected by
local inoculation of 104 cfu of S. epidermidis. At day 1, infection
was confirmed by quantitative cultures of the tissue-cage fluid.
Twenty-four hours after inoculation, antibiotic therapy was started.
Each drug was given every 12 h for 4 days (total eight doses). Ap-
plication was intraperitoneal (ip) except for netilmicin, which was
given intramuscularly (im). In any experiment, one untreated ani-
mal with four cages served as a control. Tissue-cage fluid was aspi-
rated daily for quantitative culture during therapy and at days 7, II,
and 16 during follow-up.
At day 16, tissue cages were removed, under strictly aseptic con-
ditions, from animals anesthetized with fentanyl-droperidol. After
semiquantitative culture on Mueller-Hinton agar [16], tissue cages
were incubated in trypticase soy broth for 48 h. Any positive culture
identified as S. epidermidis was defined as a treatment failure if the
isolated strain had the same antimicrobial susceptibility pattern as
the inoculated strain. The antibiogram included 29 antimicrobial
agents. Each drug regimen was tested with 12 tissue cages, except
teicoplanin (n = 22) and low-dose rifampin (n = 24). Drug combi-
nations were considered synergistic if the outcome differed sig-
nificantly (P < .05) from monotherapy.
Analysis oftissue-cage fluid. Physicochemical parameters in the
infected tissue cages were evaluated by determining pH, Po2, and
I\::02' Heparin-rinsed 1-mlsyringes with 2 l-gauge hypodermic nee-
dles (Monovette; Sarstedt Rommelsdorf, FRG) were used for sam-
pling. Samples were drawn 24 h after infection with S. epidermidis
B3972, and were immediately processed in a blood gas analyzer
(ABL 300 acid-base-laboratory; Radiometer Kopenhagen, Copen-
hagen). In one-third of the samples, hemoglobin concentration ex-
ceeded 1.5 g/l. These fluids were not analyzed because ofthe buffer
capacity of hemoglobin. Blood contamination occasionally resulted
from puncture of small vessels during aspiration.
Pharmacokinetics. Pharmacokinetic studies were performed in
sterile and infected tissue cages (day 4 of infection with S. epider-
midis B3972). Every drug was injected ip, except netilmicin, which
was given im. Peak levels in serum and in tissue-cage fluid were
determined 1 and 3-5 h after the drug application, respectively.
Trough levels in cage fluid were measured at 12 ± 0.5 h. All antibi-
otic levels were measured by agar diffusion bioassays [17]. Bacillus
subtilis (0453-360, Difco, Detroit) was used as the test strain for
ciprofloxacin, vancomycin, teicoplanin, and netilmicin; Micrococcus
luteus (ATCC 9341) was used for daptomycin. The dose-response
curves were linear in the required range. Antibiotics for the stan-
dards were diluted with pooled guinea pig serum (50%). In a large
plate (30 x 30 ern), reference standard was placed in three wells
and each sample in two wells. Standard and samples were randomly
located in different areas of the plate. Results were calculated by
microcomputer-assisted exponential regression analysis (Hewlett-
Packard HP41V).
MIC/MBC determinations. MICs were determined by the broth
dilution method supplemented with appropriate divalent cations [8].
The inoculum was adjusted from an overnight culture to a concen-
tration of 5 x lOS cfu/ml. MBCs were performed according to the
Manual ofClinical Microbiology [9]. The antibiotic concentration,
which reduced the initial inoculum>99.9%, was read as MBC. MBCs
were also determined with bacteria in the stationary phase of growth.
For this purpose, we modified the standard method by replacing
Mueller-Hinton broth by 0.25 % glucose-supplemented phosphate-
buffered saline (PBS), pH 7.4. Under these conditions, bacterial
counts remained in the same range~36 h. For daptomycin, glucose-
supplemented (0.25%) NaCI 0.9%, adjusted for pH 7.4 with natri-
umbicarbonate, was used to provide an ionized Ca'" level of ~50
mg/1. Ionized Ca'" levels were determined for any solution used for
daptomycin (Nova 2, ionized calcium analyzer; Novabiochemicals,
Newton, MA). This concentration of ionized Ca'" enables dap-
tomycin'santimicrobial activity in vitro [18]. Experiments were per-
formed in triplicate.
Time-kill curves. Time-kill curves of bacteria in the logarithmic
phase of growth were performed in Catt-supplemented Mueller-
Hinton broth [9]. For kill curves of bacteria in the stationary phase
of growth, broth was replaced by glucose-supplemented PBS, pH
7.4. For daptomycin, we used NaCI (0.9 %) adjusted with bicarbonate
to a pH 7.4 with the above mentioned supplements. Drug concen-
trations that correspond to standard MBCs were used to kill curves
[9]. Samples for plating were diluted lO-fold to minimize antibiotic
carryover. The number of cfu was determined at 2,4,6, 8, 12, and
24 h, respectively, by plating appropriate dilutions ofthe culture on
Mueller-Hinton agar. The test was processed in a room at a con-
stant 35°C to avoid unstable temperatures during handling.
Killing ofadherent bacteria. To investigate the antimicrobial ac-
tivity against adherent bacteria, we developed a novel test proce-
dure. Glass slides (35 x 75 mm) were washed in alcohol! acetone
and placed vertically in racks that were transferred in gas-sterilized
polyacetal dishes (100 x 80 x 90 mm) (Semadeni AG, Ostermun-
digen, Switzerland). S. epidermidis B3972 was suspended from a
fresh overnight culture in 250 ml of sterile 0.25 % glucose-sup-
plemented PBS (pH 7.4) at a final concentration of 8 x 103 cfu/ml
and then placed in the dishes.
The inoculum was confirmed by plating 0.1 ml directly from each
dish onto agar. Four slides, placed in the rack, were incubated in
each dish for 24 h with agitation (90 rpm) at 35°C. Continuous agi-
tation prevented clusters of adherent bacteria. After this attachment
period, bacterial suspensionwasdiscarded, and all slideswere washed
three times in a 0.9% solution of sterile saline. Both sides of two
slides served as controls (adherent inoculum) and were slightly
pressed with a forceps on Mueller-Hinton agar petri dishes. Care
was taken to keep slides in contact with the agar and to avoid air
bubbles. We assumed that any adherent microorganism gave a copy
of itself on the agar. The other two slides were transferred with the
rack in Ca'" (50 mg/l)-supplemented trypticase soy broth (1'5B)
containing antibiotics. This rack was agitated (90 rpm) for another
24 h at 35°C at drug concentrations corresponding to twofoldMBCs
determined in the logarithmic phase of growth. Again, samples were
washed before being pressed on Mueller-Hinton agar. Colonies of
controls and samples were counted and expressed as colony-forming
units per slide. Experiments were excluded from analysis if adher-
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Table 1. Pharmacokinetic studies of antibiotic levels and MIC of Staphylococcus epidermidis B3972.
2.8 (2.7)
3.8 (4.2)
3.9 (1.9)
3.7 (0.5)
1.8 (2.2)
3.5 (13.9)
62 (20.3)
Ratio of trough
level to MIC+
1.0
1.0
2.0
2.0
0.06
0.031
0.031
MIC
(ug/ml)Guinea pig Humant Peak Trough
22 25 8.6 (13.9) 2.8 (2.71)
15 15 6.3 (10.14) 3.8 (4.15)
15 20 9.6 (14.1) 7.7 (3.7)
67 30 36 (7.01) 7.3 (0.97)
3.1 2 0.95 (0.34) 0.11 (0.13)
0.49 12 0.35 (0.8) 0.11 (0.40)
14.5 12 8.3 (6.32) 1.88 (0.63)
15
5
6.6
20
10
7.5
25
Dose Peak level in serum (I!g/ml) Level in cage fluids+ (I!g/ml)
Antibiotic (mg/kg)*
Vancomycin
Daptomycin
Teicoplanin
Netilmicin
Ciprofloxacin
Rifampin
Rifampin
NOTE. MIC - minimum inhibitory concentration.
; Drugs were administered twice.daily. Netilmi~in was administered intramuscularly; all others were administered intraperitoneally.
Average of serum peak levels In humans provided by respective manufacturers.
:/: Ratios in parentheses calculated with the results of infected tissue-cage fluid.
ent bacteria of the controls were <102 or >103 cfu per slide so that
each experiment had similar adherent inocula. The percentage kill
rate was calculated as 100 - [(cfu per slide on drug-incubated
slides)/(cfu per slide on control slides)] x 100.
Statistics. Fisher's exact test was performed for animal studies.
Variance component analysis was done for adherence studies using
a statistical software (SAS Institute, Cary, NC).
Results
Pharmacokinetics. Table 1 compares the pharmacokinetic
studies in guinea pigs with the MIC ofthe corresponding drug.
For each antibiotic a dosage was chosen that resulted in peak
serum levels near those suggested by the drug's manufacturer.
With these regimens, peaklevels in sterile cage fluids exceeded
MBCs for every experimental drug. Trough levels in sterile
fluids were below the MBC, but still above MICs for van-
comycin, ciprofloxacin, and netilmicin (tables 1 and 2}. The
ratio ofthe trough level in sterile cage fluid to MIC was simi-
lar for all drugs (1.8-3.9) except rifampin (table 1). The trough
level in sterile tissue-cage fluid of the regular rifampin regi-
men (25 mg/kg) exceeded the MIC 62 times. Thus, we also
tested rifampin at a lower dose (7.5 mg/kg) , providing a trough
level:MIC ratio in the same range as the other drugs. Antibi-
otic levels in infected tissue-cage fluids (table 1, values in
parentheses) were in the same range as in sterile fluids, ex-
cept for netilmicin. As could be expected, these levels were
lower in infected than in sterile tissue-cage fluid [19].
TIssue-cage infection. Infection of all cages was initiated
by an initial inoculum of f\.IIQ4 cfu of S. epidermidis B3972
or S. epidermidis ATCC 35983. In control animals, bacterial
counts in aspiration fluid fluctuated from 103 to lOS cfu/ml
regardless of the initial inoculum. '
Treatment results are summarized in figure 1. No sponta-
neous healing of implant infections occurred in 60 untreated
cages, not even after a prolonged (3-month) observation (n =
4). The infection remained localized around the tissue cages.
Infected tissue cages were expelled after f\.I3 months. Spon-
taneous contamination of the cage fluid was observed during
the experiment in 5%-10% , mostly due to gram-negative rods.
The emergence of resistance was not observed with any an-
tibiotic regimen.
Teicoplanin and ciprofloxacin, respectively, were the least
efficient drugs; rifampin had the highest efficacy (P< .001).
Ciprofloxacin did not reduce bacterial counts during treat-
ment (data not shown). The addition ofnetilmicin to daptomy-
cin significantly improved the cure rate (P < .01). Synergy
could not be demonstrated when netilmicin was combined with
vancomycin. Rifampin was the only drug that sterilized any
implant infection, mostly within 48 h after the start of treat-
ment. With low-dose therapy (7.5 mg/kg), bacterial counts
fell below the limit of detection, but in 25 % relapse with the
same rifampin-sensitive strain occurred. This recurrence could
be avoided by adding ciprofloxacin to low-dose rifampin. This
combination failed to cure any implant (0 of 12) infected by
the rifampin-resistant S. epidermidisB3972 variant. In all ex-
periments shown in figure 1, treatment was started 24 h after
inoculation. For rifampin, the most efficient drug, this inter-
val was prolonged to 1 week (3 and 7 days)..Rifampin (25 mg!
kg) sterilized all 12 implant infections, even when started 7
days after bacterial inoculation.
To check the importance of slime production on antibiotic
efficacy, we performed two more series of experiments with
S. epidermidis ATCC 35983, known to be a moderate to strong
Table 2. Minimum bactericidal concentration (MBC) of Staph-
ylococcus epidermidis B3972.
Phases of bacterial
growth (ug/ml)
Fold
Antibiotic Logarithmic Stationary increase
Vancomycin 4 50 12.5
Daptomycin 2 12.5 6
Teicoplanin 4 12.5 3
Ciprofloxacin 0.5 100 200
Rifampin 0.06 0.15 2.5
Netilrnicin 8 400 50
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Antibiotic Regimen
mg/kg bid
Controls
~••••••••••1111••'" 100%Ciprofloxacin 10+ Rifampin 7.5 ~
17%
Figure 1. Cure rate of tissue-cage
infections with Staphylococcus
epidermidis B397~. Guinea pigs
with tissue-eage implants were treated
with antibiotics as indicated on the
y axis. Numbers of infections: con-
trols, 60; antibiotics, 12 each, ex-
cept teicoplanin, 22, and rifampin
(7.5 mg/kg), 24. Rifampin at 25
mg/kg was significantly more effi-
cient than at 7.5 mg/kg (P < .01,
Fisher~ exact tesQ.
Teicoplanin 6.6
Ciprofloxacin 10
17%
75%
0% 20% 40% 60% 80% 100%
% Cure Rate of Tissue Cages
slime producer [14]. With this strain also, any tissue cage (n =
8) in control animals remained infected during the experiment.
Rifampin (25 mg/kg) still sterilized a1112 tissue cages, whereas
ciprofloxacin did not cure any infection (0 of 12).
Characteristics oftissue-cagefluid. In view of the differ-
ent cure rates by antibiotics that reached local levels exceed-
ing MICs at any time, we analyzed some characteristics of
the infected tissue-cage fluids that might influence the in vivo
efficacy of antibiotics. A slight acidosis (pH 7.18 ± 0.04, n =
12) and a moderately decreased Po. (7.67 ± 0.7 kPa) were
measured.
MBCs and time-kill curves in stationary and logarithmic
phases of bacterial growth. Microorganisms involved in
implant-associated infections may be in stationary growth
phases. We thus sought in vitro tests with a better predictive
value than the standard MIC and MBC, which are determined
in the logarithmic phase of growth [9]. Table 2 shows that
MBCs of S. epidermidis B3972 determined with bacteria in
the stationary growth phase were up to 200 times higher
(ciprofloxacin) than obtained with bacteria in the logarithmic
phase of growth. Rifampin, teicoplanin, and daptomycin all
had almost the same efficacy on nongrowing as on growing
staphylococci. To further characterize these observations, we
performed kill curves in stationary and logarithmic growth
phases. The results of representative experiments are sum-
marized in figures 2 and 3. Figure 2 shows drugs with dimin-
ished activity on nongrowing bacteria. In contrast, rifampin
and teicoplanin (figure 3) had a nearly identical killing rate
in both systems. However, rifampin acted much faster than
Figure 2. Time-kill studies of Staphylococcus epidermidis B3972.
Concentration of antibiotic corresponds to minimum bactericidal
concentration in logarithmic phase of growth. Controls and antibi-
otics in logarithmic growth phases, respectively (D, _,); controls
and antibiotics in stationary growth phases, respectively (0, .).
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in device-related infections bacterial adhesion is crucial, we
tested an additional parameter, drug efficacyon adherent bac-
teria. With an initial inoculum of 8 x 1()3 cfu/ml, 330 ± 13
cfu per slide (mean ± SE, n = 92) adhered to the glass slides.
More than 103 cfu per slide adhered with inocula exceeding
8 x 1Q4 cfu/ml. The variability among different assays with
the same drug was always lower than among different drugs
(F = 11.86, P < .01), confirming the reproducibility of the
assay. Figure 4 summarizes the results of four or more ex-
periments. Rifampin was the most efficient drug with a mean
killing rate of 99.7%by incubation of adherent bacteria at the
doubled MBC.
109
Teicoplanin 4J.lg/ml
108
107
8 10
6
..... lOS
.E
0
104
103
102
0 2 4 6 10 12 14 16 18 20 22 24
time (hours)
Figure 3. Time kill studies of Staphylococcal epidermidis B3972.
Concentration of antibiotic corresponds to minimum bacterical con-
centration in logarithmic growth phase. Controls and antibiotics in
logarithmic growth phase (0, _); controls and antibiotics in sta-
tionary growth phases (0, .).
teicoplanin. In the time-kill curve, teicoplanin (4 p,g/ml)
showed a killing rate of >99.9%, which contrasted with the
stationary MBC of 12.5 p,g/ml; however, this may be due to
the different techniques used. The antibiotic combinations used
in the animal model did not improve the killing by the single
agent (data not shown).
Drug efficacy on adherent S. epidermidis B3972. Since
Antibiotic
Discussion
We previously analyzed host defense mechanisms in the an-
imal model used in this study [2, 3, 12]. Similar to humans,
guinea pigs are highly susceptible to foreign-body infections
[3]. Thus this model was used to test antibiotics for their ability
to sterilize device-related infections. Clinical data concern-
ing the antibiotic treatment of such infections are scarce and
difficult to interpret. Therefore, criteria for surgical versus
antibiotic treatment of the different implant infections are not
well established [1]. This reflects the difficulty in performing
clinical studies under controlled conditions with unambigu-
ous criteria to determine efficacy after prolonged follow-up
periods.
To enable attachment and adherence of bacteria to the im-
plant [5], we started the antimicrobial treatment not earlier
than 24 h after inoculation. Short-term therapy was chosen
for detecting antimicrobial agents with excellent efficacy. Ri-
fampin was the most efficient drug; however, the extremely
low MIC compared to the tissue-cage trough level could be
a trivial explanation for its high efficacy. To correct for this,
we used a low-dose regimen of rifampin that resulted in a ra-
tio of trough level in tissue-cage fluid to MIC similar to that
of the other drugs. At this low dose, rifampin was still the
most efficient drug.
Ciprofloxacin11lg/ml
Vancomycin81lglml
Netilmicin161lglml
Teicoplanin81lg/ml
Daptomycin 4Ilg/ml
RifampinO.121lg/ml
Figure 4. Log killing of adherent Staph-
ylococcus epidermidis B3972. Assay was
performed at drug concentrations twice the
minimum bactericidal concentrations. Con-
centrations are shown on y axis. Killing rate
was determined as follows: 100 - [(cfu per
slide on drug incubated slides)/(cfu per slide
on control slides)] x 100, expressed as
10glO killing.
0.0 0.5 1.0 1.5
Log Killing
2.0 2.5 3.0
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Ciprofloxacin had no detectable efficacy in the animal
model. This failure could not be predicted by the standard
MIC, which exceeded sterile and infected tissue-cage fluid
trough levels twofold. The slightly decreased pH of the in-
fected tissue-cage fluid could not explain the lack of an-
timicrobial activity.
In contrast to regular MICs and MBCs, bacterial MBCs
under stationary growth phase were predictive for the out-
come of tissue-cage infections. The low performance of ci-
profloxacin on nongrowing bacteria was surprising since Zeiler
and Grohe [20] showed a high efficacy of this antibiotic on
Escherichiacoli in1he stationary phase. However, this qual-
ity of ciprofloxacin was later shown to be specific for some
gram-negative rods [21, 22]. The low antistaphylococcal ac-
tivity of cyprofloxacinhas also been confirmed byclinical data.
Greenberg et al. [23] reported that none of six patients with
osteomyelitis caused by Staphylococcus aureus (monoculture)
was cured with ciprofloxacin therapy.
In our experiments the stationary-phase MBC wassurpassed
only by the tissue-cage peak and trough levels in animals
receiving rifampin. This was the sole single-drug regimen with
a high success rate. Several authors have reported the rapid
emergence of rifampin-resistant staphylococci during exposure
to this drug [24, 25]. Unlike Archer et al. [25], we did not
detect the emergence of rifampin-resistant S.· epidermidis dur-
ing treatment with rifampin, probably because the bacterial
counts in tissue-cage fluid remained at a low level. Neverthe-
less, in treatment of human infections, rifampin should al-
ways be used in combination with other drugs. Vancomycin,
which has a much lower volume of distribution than rifam-
pin, is probably not the ideal drug to combine with rifampin
[26, 27]. Thus, we tested the effect of ciprofloxacin in combina-
tion with low-dose rifampin. The improved cure rate indicates
in vivo synergism of this combination. We also sought a pos-
sible nonantimicrobial effect of rifampin (e.g., antiadhesive
potency) and repeated this experiment with the rifampin-resis-
tant variant. This combination did not cure any tissue-cage
infection, thus precluding a nonspecific effect of rifampin.
As a further diagnostic parameter for the antimicrobial ac-
tivity in foreign-body infections, we measured the killing of
in vitro adherent bacteria by antibiotics. Our assay proved sim-
ple and reproducible because the variability among different
assays with the same drug was always lower than between
different drugs.
Although the assay is fastidious, there are several possible
pitfalls. The number of adherent bacteria is crucial. Also, poly-
acetal dishes give better reproducible results than glass dishes
(data not shown), and the adherent bacteria on each slide re-
produce better if the dishes are gently agitated during the
whole procedure. With this assay, rifampin again had excel-
lent efficacy. The drug was the only one that eliminated >2.5
logs of the adherent bacteria after incubation for 24 h in a
drug concentration corresponding to twofold MBC. The ex-
cellent efficacy of rifampin in our in vitro assay and in the
animal model concurs with that found in arterial graft infec-
tions in dogs [7].
Daptomycin and teicoplanin were the second best antibiot-
ics, with a 1.7-10g killing of adherent S. epidermidis. This con-
trasted with the poor in vivo results of teicoplanin. However,
the drug concentration in tissue-cage fluid at trough levels did
not exceed the stationary-phase MBC. Possibly the failure of
teicoplanin was due to insufficient drug levels such as reported
in clinical studies [28]. Daptomycin may also have been used
at inadequate levels. All other antibiotics tested killed <1 log
of adherent microorganisms. Ciprofloxacin again had the
lowest activity. Gristina et al. [29] had similar findings with
another method. They recently showed that adherent
coagulase-negative staphylococci have generally higher MBCs
than do planktonic bacteria.
In conclusion, drug efficacy in the treatment of device-
related experimental S. epidermidis infections may be pre-
dicted by the described in vitro assays. In view of our
experimental data, we treated some staphylococcal infec-
tionsassociated with orthopedic implants with an antibiotic
combination containing rifampin. With follow-up observa-
tions of >1 year, disappearance of signs of inflammation
could be observed (unpublished data). These preliminary data
should be confirmed in a controlled clinical trial with the
described assays as a guide for the choice of antibiotics.
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